MAP3K5 and cancer: AMRI-59 has been characterized as an anti-cancer candidate as well as an inhibitor of PRX I via disruption of ROS, and deregulation of ROS is known to ultimately trigger cancer cell death through activation of both mitochondria- and apoptosis signal-regulated kinase-1-mediated signaling pathways.